The tweet was deleted by the author.
But we saved everything 🙂.
Tenaya Therapeutics announced the latest interim clinical data from its MyPEAK-1 Phase 1b/2 trial for TN-201.
The data was shared by Dr. Milind Desai during the #AHA25 conference, highlighting advancements in gene therapy for heart disease treatment. Those who missed the presentation can access the webcast on Monday. Interested parties are encouraged to view the press release for further information.
The recent clinical developments from Tenaya Therapeutics build on the company's momentum established during previous research milestones. For a deeper understanding of how Tenaya's progress at AHA25 sessions with experts like Dr. Milind Desai and Dr. Kathy Ivey has shaped the current landscape, see the earlier coverage of advancements at AHA25 sessions.